[go: up one dir, main page]

FR2848451B1 - PROCESS FOR THE CHEMICAL STABILIZATION OF A SOLUBILIZED RETINOID AND AQUEOUS COMPOSITION OBTAINED BY THE PROCESS COMPRISING AT LEAST ONE RETINOID IN SALIVED FORM - Google Patents

PROCESS FOR THE CHEMICAL STABILIZATION OF A SOLUBILIZED RETINOID AND AQUEOUS COMPOSITION OBTAINED BY THE PROCESS COMPRISING AT LEAST ONE RETINOID IN SALIVED FORM

Info

Publication number
FR2848451B1
FR2848451B1 FR0216017A FR0216017A FR2848451B1 FR 2848451 B1 FR2848451 B1 FR 2848451B1 FR 0216017 A FR0216017 A FR 0216017A FR 0216017 A FR0216017 A FR 0216017A FR 2848451 B1 FR2848451 B1 FR 2848451B1
Authority
FR
France
Prior art keywords
retinoid
salived
aqueous composition
composition obtained
solubilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0216017A
Other languages
French (fr)
Other versions
FR2848451A1 (en
Inventor
Agnes Ferrandis
Sandrine Orsoni
Laurent Fredon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0216017A priority Critical patent/FR2848451B1/en
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to JP2004560489A priority patent/JP2006511547A/en
Priority to PCT/EP2003/015041 priority patent/WO2004054543A1/en
Priority to RU2005122467/15A priority patent/RU2005122467A/en
Priority to BR0316892-1A priority patent/BR0316892A/en
Priority to CA002510038A priority patent/CA2510038A1/en
Priority to PL377430A priority patent/PL377430A1/en
Priority to MXPA05006082A priority patent/MXPA05006082A/en
Priority to AU2003296758A priority patent/AU2003296758A1/en
Priority to KR1020057011272A priority patent/KR20050085740A/en
Priority to EP03813148A priority patent/EP1575557A1/en
Priority to CNA2003801066839A priority patent/CN1728983A/en
Priority to ARP030104669A priority patent/AR042498A1/en
Publication of FR2848451A1 publication Critical patent/FR2848451A1/en
Priority to US11/154,655 priority patent/US20050288374A1/en
Priority to ZA200505124A priority patent/ZA200505124B/en
Application granted granted Critical
Publication of FR2848451B1 publication Critical patent/FR2848451B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
FR0216017A 2002-12-17 2002-12-17 PROCESS FOR THE CHEMICAL STABILIZATION OF A SOLUBILIZED RETINOID AND AQUEOUS COMPOSITION OBTAINED BY THE PROCESS COMPRISING AT LEAST ONE RETINOID IN SALIVED FORM Expired - Fee Related FR2848451B1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR0216017A FR2848451B1 (en) 2002-12-17 2002-12-17 PROCESS FOR THE CHEMICAL STABILIZATION OF A SOLUBILIZED RETINOID AND AQUEOUS COMPOSITION OBTAINED BY THE PROCESS COMPRISING AT LEAST ONE RETINOID IN SALIVED FORM
EP03813148A EP1575557A1 (en) 2002-12-17 2003-12-16 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
RU2005122467/15A RU2005122467A (en) 2002-12-17 2003-12-16 METHOD FOR CHEMICAL STABILIZATION OF MOBILIZED RETINOID AND WATER COMPOSITION OBTAINED BY THIS METHOD CONTAINING AT LEAST ONE RETINOID IN THE FORM OF SALT
BR0316892-1A BR0316892A (en) 2002-12-17 2003-12-16 Process for chemical stabilization of a solubilized retinoid, aqueous composition, use of a composition, cosmetic use of a composition and use of a base
CA002510038A CA2510038A1 (en) 2002-12-17 2003-12-16 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
PL377430A PL377430A1 (en) 2002-12-17 2003-12-16 A method of chemical stabilization of a solubilized retinoid in a solvent using a base
MXPA05006082A MXPA05006082A (en) 2002-12-17 2003-12-16 PROCESS FOR CHEMICAL STABILIZATION OF A RETINOID SOLUBILIZED IN A SOLVENT USING A BASE.
AU2003296758A AU2003296758A1 (en) 2002-12-17 2003-12-16 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
JP2004560489A JP2006511547A (en) 2002-12-17 2003-12-16 Method for chemical stabilization of solubilized retinoids in a solvent using a base
PCT/EP2003/015041 WO2004054543A1 (en) 2002-12-17 2003-12-16 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
CNA2003801066839A CN1728983A (en) 2002-12-17 2003-12-16 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
KR1020057011272A KR20050085740A (en) 2002-12-17 2003-12-16 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
ARP030104669A AR042498A1 (en) 2002-12-17 2003-12-17 CHEMICAL STABILIZATION PROCEDURE OF A SOLUBILIZED RETINOID AND COMPOSITION OBTAINED ACCORDING TO THE PROCEDURE THAT INCLUDES AT LEAST ONE RETINOID IN SALIFIED FORM
US11/154,655 US20050288374A1 (en) 2002-12-17 2005-06-17 Chemical stabilization of solubilized retinoids and aqueous compositions comprised thereof
ZA200505124A ZA200505124B (en) 2002-12-17 2005-06-24 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0216017A FR2848451B1 (en) 2002-12-17 2002-12-17 PROCESS FOR THE CHEMICAL STABILIZATION OF A SOLUBILIZED RETINOID AND AQUEOUS COMPOSITION OBTAINED BY THE PROCESS COMPRISING AT LEAST ONE RETINOID IN SALIVED FORM

Publications (2)

Publication Number Publication Date
FR2848451A1 FR2848451A1 (en) 2004-06-18
FR2848451B1 true FR2848451B1 (en) 2007-01-12

Family

ID=32338901

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0216017A Expired - Fee Related FR2848451B1 (en) 2002-12-17 2002-12-17 PROCESS FOR THE CHEMICAL STABILIZATION OF A SOLUBILIZED RETINOID AND AQUEOUS COMPOSITION OBTAINED BY THE PROCESS COMPRISING AT LEAST ONE RETINOID IN SALIVED FORM

Country Status (4)

Country Link
CN (1) CN1728983A (en)
AR (1) AR042498A1 (en)
FR (1) FR2848451B1 (en)
ZA (1) ZA200505124B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2991176B1 (en) * 2012-06-01 2014-12-19 Galderma Res & Dev TOPICAL COMPOSITIONS CONTAINING SOLUBILIZED RETINOID OF HYDROGLYCOLIC GEL TYPE
US9244054B2 (en) * 2012-07-10 2016-01-26 GM Global Technology Operations LLC Systems and methods for determining a state of deterioration of engine oil using multiple preselected oil properties

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601670B1 (en) * 1986-07-17 1988-10-07 Cird NOVEL AROMATIC BICYCLIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS
FR2647015B1 (en) * 1989-05-17 1994-05-06 Cird AQUEOUS GEL BASED ON RETINOIC ACID AND ITS USE IN HUMAN MEDICINE AND COSMETICS
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
FR2731706B1 (en) * 1995-03-14 1997-04-11 Cird Galderma AROMATIC HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES
JP4061015B2 (en) * 2000-10-30 2008-03-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Drug-containing composition having retinoic acid receptor agonistic action

Also Published As

Publication number Publication date
FR2848451A1 (en) 2004-06-18
AR042498A1 (en) 2005-06-22
ZA200505124B (en) 2007-03-28
CN1728983A (en) 2006-02-01

Similar Documents

Publication Publication Date Title
PL370779A1 (en) Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments
WO2006017055A3 (en) Pyrazole amide derivatives, compositions containing such compounds and methods of use
SI1605932T1 (en) Intranasal formulation of rotigotine
WO2001066564A3 (en) Gamma-secretase inhibitors
FR08C0052I2 (en) 6-MERCAPTO-CYCLODEXTRIN DERIVATIVES: AGENTS FOR REVERSING NEUROMUSCULAR BLOCKAGE CAUSED BY DRUG SUBSTANCES
NZ515902A (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes
DE60118067D1 (en) Pharmaceutical composition containing dystrophin exon 45 for the treatment of Duchenne muscular dystrophy
IT1304501B1 (en) USE OF BILIARY ACID DERIVATIVES CONJUGATED WITH METALLIC COMPLEXES LIKE "BLOOD POOL AGENTS" FOR THE DIAGNOSTIC INVESTIGATION THROUGH RESONANCE
EP2085086A3 (en) Method for treating congestive heart failure or diabetic nephropathy
EP2338886A3 (en) Naphthalene derivatives
HUP0401160A3 (en) 2,4,5-trisubstituted thiazolyl derivatives having antiinflammatory activity, process for their preparation and pharmaceutical compositions containing them
EP2168962A3 (en) Phenylacetamides and their use as glucokinase modulators
ES2132190T3 (en) CYCLODEXTRIN COMPLEX.
DK1087934T3 (en) Aminocyclohexyl ether compounds and uses thereof
MA25827A1 (en) BENZOYLPYRIDINE DERIVATIVES OR ITS SALT, FUNGICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT, PROCESS FOR PRODUCING THE SAME AND INTERMEDIATE FOR PRODUCING THE SAME.
BG106681A (en) Solutions containing epinastine
DZ3156A1 (en) New polymorphic form of the salt of 5-Ä4-Ä2- (n-methyl-n- (2-pyridyl) amino) ethoxyÜbenzylÜthiazolidine-2,4-dione, maleic acid.
KR910000620A (en) N-substituted laurylamide, preparation method thereof
EP1133979A3 (en) Use of specific fatty compounds for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon
FR2848451B1 (en) PROCESS FOR THE CHEMICAL STABILIZATION OF A SOLUBILIZED RETINOID AND AQUEOUS COMPOSITION OBTAINED BY THE PROCESS COMPRISING AT LEAST ONE RETINOID IN SALIVED FORM
EP0952159A3 (en) Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents
EP2044958A3 (en) Pharmaceutical composition for treating arteriosclerosis
FR2823992B1 (en) HYDROXYAPATITE DISPERSIONS COMPRISING AN AMINO ACID AS A STABILIZING AGENT, AND THEIR PREPARATION PROCESS
DE60115997D1 (en) 1,1- and 1,2-Disubstituted cyclopropanes, processes for their preparation and their pharmaceutical compositions
DE69808475D1 (en) AMINO ACID DERIVATIVES FOR TREATING STROKE

Legal Events

Date Code Title Description
CA Change of address
ST Notification of lapse

Effective date: 20090831